These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 24354853)

  • 1. A pandemic H1N1 influenza virus-like particle vaccine induces cross-protection in mice.
    Inn KS; Lee GJ; Quan FS
    Immunol Invest; 2014; 43(3):236-54. PubMed ID: 24354853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.
    Quan FS; Huang C; Compans RW; Kang SM
    J Virol; 2007 Apr; 81(7):3514-24. PubMed ID: 17251294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice.
    Quan FS; Vunnava A; Compans RW; Kang SM
    PLoS One; 2010 Feb; 5(2):e9161. PubMed ID: 20161790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virus-like particle vaccine comprised of the HA, NA, and M1 proteins of an avian isolated H5N1 influenza virus induces protective immunity against homologous and heterologous strains in mice.
    Tao P; Luo M; Zhu D; Qu S; Yang Z; Gao M; Guo D; Pan Z
    Viral Immunol; 2009 Jul; 22(4):273-81. PubMed ID: 19594398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice.
    Abdoli A; Soleimanjahi H; Tavassoti Kheiri M; Jamali A; Mazaheri V; Abdollahpour Alitappeh M
    Pathog Dis; 2014 Dec; 72(3):197-207. PubMed ID: 25066138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1).
    Matassov D; Cupo A; Galarza JM
    Viral Immunol; 2007 Sep; 20(3):441-52. PubMed ID: 17931114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
    Wang Y; Wu J; Xue C; Wu Z; Lin Y; Wei Y; Wei X; Qin J; Zhang Y; Wen Z; Chen L; Liu GD; Cao Y
    Antiviral Res; 2017 Jul; 143():97-105. PubMed ID: 28408133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge.
    Galarza JM; Latham T; Cupo A
    Viral Immunol; 2005; 18(2):365-72. PubMed ID: 16035948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza.
    Hossain MJ; Bourgeois M; Quan FS; Lipatov AS; Song JM; Chen LM; Compans RW; York I; Kang SM; Donis RO
    Clin Vaccine Immunol; 2011 Dec; 18(12):2010-7. PubMed ID: 22030367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection induced by early stage vaccination with pandemic influenza virus-like particles.
    Lee GJ; Quan FS
    Vaccine; 2016 Jul; 34(33):3764-72. PubMed ID: 27317263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses.
    Carter DM; Darby CA; Lefoley BC; Crevar CJ; Alefantis T; Oomen R; Anderson SF; Strugnell T; Cortés-Garcia G; Vogel TU; Parrington M; Kleanthous H; Ross TM
    J Virol; 2016 May; 90(9):4720-4734. PubMed ID: 26912624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
    Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
    Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
    Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
    Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Correlates of Protection Induced by Virus-Like Particles Containing 2009 H1N1 Pandemic Influenza HA, NA or M1 Proteins.
    Moon EK; Kang HJ; Chu KB; Lee SH; Lee DH; Soh Y; Quan FS
    Immunol Invest; 2019 May; 48(4):355-366. PubMed ID: 30430891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pandemic H1N1 influenza virus-like particles are immunogenic and provide protective immunity to pigs.
    Pyo HM; Masic A; Woldeab N; Embury-Hyatt C; Lin L; Shin YK; Song JY; Babiuk S; Zhou Y
    Vaccine; 2012 Feb; 30(7):1297-304. PubMed ID: 22207090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine Efficacy Induced by 2009 Pandemic H1N1 Virus-Like Particles Differs from that Induced by Split Influenza Virus.
    Lee GJ; Chu KB; Inn KS; Moon EK; Quan FS
    Immunol Invest; 2020 Oct; 49(7):781-793. PubMed ID: 31774021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.
    Wu CY; Yeh YC; Chan JT; Yang YC; Yang JR; Liu MT; Wu HS; Hsiao PW
    PLoS One; 2012; 7(8):e42363. PubMed ID: 22879951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.